1. Lam JO, Hou CE, Lee C, Samiezade-Yazd Z, et al.
   Hypertension control and risk of age-associated dementia in people with hiv infection.
   AIDS 2024.
   


2. Yadav A, Gionet G, Karaj A, Kossenkov AV, et al.
   Association of smoking with neurocognition, inflammatory and myeloid cell activation profiles in people with HIV on ART.
   AIDS 2024.
   


3. Ueland T, Nkele I, Hoel H, Lockman S, et al.
   Markers of extracellular matrix degradation and inflammasome activation are associated with carotid plaques in virally suppressed people with HIV in Botswana.
   AIDS 2024.
   


4. Filip I.
   Twice-yearly lenacapavir may change the standard of HIV prevention for women.
   AIDS 2024.
   


5. Overton ET, Kantor A, Fitch KV, Mosepele M, et al.
   Proteinuria and albuminuria among a global primary CVD prevention cohort of PWH: prevalence and associated factors.
   AIDS 2024.
   


6. Schurmann D, Hueser A, Pfaefflin F, Cilissen C, et al.
   A Randomized, Double-blind, Placebo-controlled, Short-term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), in Treatment-Naive HIV-Infected Participants.
   AIDS Res Hum Retroviruses 2024.
   


7. Su X, Freeman M.
   CD57+ T cell transmigration through vascular endothelial cells is enhanced by TNF: A novel model of cardiovascular risk in people with HIV.
   AIDS Res Hum Retroviruses 2024.
   


8. Jia J, Yang H, Zhang Z, Shi H, et al.
   Characterization of Two Novel HIV-1 CRF01_AE/ CRF07_BC Recombinant Forms Among Men Who Have Sex with Men and Mother-to-Child Transmission Cases in Baoding City, China.
   AIDS Res Hum Retroviruses 2024.
   


9. Bedimo R, Hardy D, Lee D, Palella F, et al.
   Expert Consensus Statement on an Updated Definition of Unintended Weight Loss Among Persons With Human Immunodeficiency Virus in the Modern Treatment Era.
   Clin Infect Dis 2024;79:S63-S75.
   


10. Gutierrez F, Fernandez-Gonzalez M, Ledesma C, Losada-Echeberria M, et al.
    Virological History Predicts Non-sustained Viral Suppression with Long-Acting Cabotegravir and Rilpivirine Therapy, independent of Pharmacokinetic Parameters.
    Clin Infect Dis 2024.
    


11. Martin-Carmona J, Corma-Gomez A, Tellez F, Arenga-Barrios D, et al.
    No impact of HIV coinfection on the mortality in patients with hepatitis C virus infection after sustained virological response.
    Clin Infect Dis 2024.
    


12. Joly V, Ferre VM, Le Hingrat Q, Peytavin G, et al.
    Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study.
    Clin Infect Dis 2024.
    


13. Jalil CM, Maia Teixeira SL, Coutinho C, Nazer SC, et al.
    Impact of Covid-19 pandemic on HIV testing, recent infections and annualized incidence among cisgender men who have sex with men and transgender women in Brazil.
    J Acquir Immune Defic Syndr 2024.
    


14. Selzer L, VanderVeen LA, Parvangada A, Martin R, et al.
    Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People with HIV-1 Suppressed by Antiretroviral Therapy.
    J Acquir Immune Defic Syndr 2024.
    


15. Angulique O, Thomas T, Karen M, Monique J, et al.
    Motivational Enhancement System for Adherence (MESA) for Adolescents and Young Adults Newly Recommended to Start Antiretroviral Therapy (ART).
    J Acquir Immune Defic Syndr 2024.
    


16. Corbett C, van Rensburg R, Brey N, O'Hagan S, et al.
    Timing of ART initiation associated with HIV-associated stroke.
    J Acquir Immune Defic Syndr 2024.
    


17. Neary J, Njuguna I, Wagner AD, Richardson BA, et al.
    Brief Report: Group-Based Trajectory Modeling to Determine Long-Term HIV Viral Load Trends Among Children With HIV in Kenya.
    J Acquir Immune Defic Syndr 2024;96:311-317.
    


18. Cyktor JC, Yeh E, Ribaudo H, Hoeth D, et al.
    Brief Report: Low-Dose Methotrexate Does Not Affect Measures of HIV-1 Persistence in Individuals With Chronically Treated HIV-1 Infection.
    J Acquir Immune Defic Syndr 2024;96:481-485.
    


19. Mihealsick E, Word A, Scully EP.
    The impact of sex on HIV immunopathogenesis and therapeutic interventions.
    J Clin Invest 2024;134.
    


20. Lin LY, Gantner P, Li S, Su B, et al.
    Unpredicted protective function of Fc-mediated inhibitory antibodies for HIV and SARS-CoV-2 vaccines.
    J Infect Dis 2024.
    


21. Rubin LH, Shirk EN, Pohlenz L, Romero H, et al.
    Intact HIV reservoir in monocytes is associated with cognitive function in virally suppressed women with HIV.
    J Infect Dis 2024.
    


22. Pan D, Mohamed B, Gupta A, Arshad Z, et al.
    Clinical and molecular epidemiology of enterovirus infections in cerebrospinal fluid samples, 2019-2023.
    J Med Virol 2024;96:e29924.
    


23. Pincus SH, Cole FM, Ober K, Tokmina-Lukaszewska M, et al.
    Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate.
    J Virol 2024.
    


24. Janevska M, Cammaert T, Naessens E, Verhasselt B, et al.
    A cGAS-mediated type I interferon response in human CD4+ T cells depends on productive infection and is conserved over HIV types and strains.
    J Virol 2024.
    

Display articles in

• Abstract format
• Medline format